Allelic variant at -79 (C>T) in CDKN1B (p27Kip1) confers an increased risk of thyroid cancer and alters mRNA levels

Endocrine-Related Cancer

Volumn 17, Issue 2, 2010, Pages 317-328

  Landa, Iñigo ^a   Montero Conde, Cristina ^a   Malanga, Donatella ^b,c   De Gisi, Silvia ^c   Pita, Guillermo ^a   Leandro García, Luis Javier ^a   Inglada Pérez, Lucía ^a   Letón, Rocío ^a   De Marco, Carmela ^b,c   Rodríguez Antona, Cristina ^a,d   Viglietto, Giuseppe ^b,c   Robledo, Mercedes ^a,d  

^a Centro Nacional de Investigaciones Oncológicas   (Spain)

^b UNIVERSITY MAGNA GRAECIA OF CATANZARO   (Italy)

^c Institute for Genetic Research IRGS   (Italy)

^d CENTRO DE INVESTIGACIÓN BIOMÉDICA EN RED DE ENFERMEDADES RARAS CIBERER   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLIN DEPENDENT KINASE INHIBITOR 1B; LUCIFERASE; MESSENGER RNA;

ARTICLE; CANCER RISK; CANCER SUSCEPTIBILITY; CONTROLLED STUDY; GENE LOCUS; GENETIC RISK; GENETIC TRANSCRIPTION; GENOTYPE; HUMAN; LYMPHOCYTE; MAJOR CLINICAL STUDY; NUCLEOTIDE SEQUENCE; PENETRANCE; PROMOTER REGION; REPORTER GENE; RISK ASSESSMENT; SINGLE NUCLEOTIDE POLYMORPHISM; THYROID FOLLICULAR CARCINOMA; THYROID MEDULLARY CARCINOMA; THYROID PAPILLARY CARCINOMA;

ADENOCARCINOMA, FOLLICULAR; ALLELES; CARCINOMA, PAPILLARY, FOLLICULAR; CASE-CONTROL STUDIES; CYCLIN-DEPENDENT KINASE INHIBITOR P27; FEMALE; HUMANS; MALE; POLYMORPHISM, GENETIC; POLYMORPHISM, SINGLE NUCLEOTIDE; RISK FACTORS; RNA, MESSENGER; SPAIN; THYROID NEOPLASMS;

EID: 77953586698     PISSN: 13510088     EISSN: 14796821     Source Type: Journal    
DOI: 10.1677/ERC-09-0016     Document Type: Article

References (52)

1. Baldassarre G, Belletti B, Bruni P, Boccia A, Trapasso F, Pentimalli F, Barone MV, Chiappetta G, Vento MT, Spiezia S et al. 1999 Overexpressed cyclin D3 contributes to retaining the growth inhibitor p27 in the cytoplasm of thyroid tumor cells. Journal of Clinical Investigation 104 865-874.
2. Cebrian A, Lesueur F, Martin S, Leyland J, Ahmed S, Luccarini C, Smith PL, Luben R, Whittaker J, Pharoah PD et al. 2005 Polymorphisms in the initiators of RET (rearranged during transfection) signaling pathway and susceptibility to sporadic medullary thyroid carcinoma. Journal of Clinical Endocrinology and Metabolism 90 6268-6274.
3. Chang BL, Zheng SL, Isaacs SD, Wiley KE, Turner A, Li G, Walsh PC, Meyers DA, Isaacs WB & Xu J 2004 A polymorphism in the CDKN1B gene is associated with increased risk of hereditary prostate cancer. Cancer Research 64 1997-1999. (Pubitemid 38339445)
4. Chiappetta G, De Marco C, Quintiero A, Califano D, Gherardi S, Malanga D, Scrima M, Montero-Conde C, Cito L, Monaco M et al. 2007 Overexpression of the S-phase kinase-associated protein 2 in thyroid cancer. Endocrine-Related Cancer 14 405-420.
5. Chu IM, Hengst L & Slingerland JM 2008 The Cdk inhibitor p27 in human cancer: prognostic potential and relevance to anticancer therapy. Nature Reviews. Cancer 8 253-267.
6. Conde L, Vaquerizas JM, Dopazo H, Arbiza L, Reumers J, Rousseau F, Schymkowitz J & Dopazo J 2006 PupaSuite: finding functional single nucleotide polymorphisms for large-scale genotyping purposes. Nucleic Acids Research 34 W621-W625.
7. Davies H, Bignell GR, Cox C, Stephens P, Edkins S, Clegg S, Teague J, Woffendin H, Garnett MJ, Bottomley W et al. 2002 Mutations of the BRAF gene in human cancer. Nature 417 949-954.
8. DeLellis RA 2004 Pathology and Genetics of Tumours of Endocrine Organs. Lyon: IARC Press.
9. Driver KE, Song H, Lesueur F, Ahmed S, Barbosa-Morais NL, Tyrer JP, Ponder BA, Easton DF, Pharoah PD & Dunning AM 2008 Association of single-nucleotide polymorphisms in the cell cycle genes with breast cancer in the British population. Carcinogenesis 29 333-341.
10. Erickson LA, Jin L, Wollan PC, Thompson GB, van Heerden J & Lloyd RV 1998 Expression of p27kip1 and Ki-67 in benign and malignant thyroid tumors. Modern Pathology 11 169-174. (Pubitemid 28144152)
11. Gayther SA, Song H, Ramus SJ, Kjaer SK, Whittemore AS, Quaye L, Tyrer J, Shadforth D, Hogdall E, Hogdall C et al. 2007 Tagging single nucleotide polymorphisms in cell cycle control genes and susceptibility to invasive epithelial ovarian cancer. Cancer Research 67 3027-3035.
12. Gonzalez P, Diez-Juan A, Coto E, Alvarez V, Reguero JR, Batalla A & Andres V 2004 A single-nucleotide polymorphism in the human p27kip1 gene (-838CO>A) affects basal promoter activity and the risk of myocardial infarction. BMC Biology 2 5.
13. Greco A, Pierotti MA, Bongarzone I, Pagliardini S, Lanzi C & Della Porta G 1992 TRK-T1 is a novel oncogene formed by the fusion of TPR and TRK genes in human papillary thyroid carcinomas. Oncogene 7 237-242.
14. Hengst L & Reed SI 1996 Translational control of p27Kip1 accumulation during the cell cycle. Science 271 1861-1864. (Pubitemid 3040861)
15. Hilger-Eversheim K, Moser M, Schorle H & Buettner R 2000 Regulatory roles of AP-2 transcription factors in vertebrate development, apoptosis and cell-cycle control. Gene 260 1-12.
16. Hofstra RM, Landsvater RM, Ceccherini I, Stulp RP, Stelwagen T, Luo Y, Pasini B, Hoppener JW, van Amstel HK, Romeo G et al. 1994 A mutation in the RET proto-oncogene associated with multiple endocrine neoplasia type 2B and sporadic medullary thyroid carcinoma. Nature 367 375-376.
17. Hou P, Liu D, Shan Y, Hu S, Studeman K, Condouris S, Wang Y, Trink A, El-Naggar AK, Tallini G et al. 2007 Genetic alterations and their relationship in the phosphatidylinositol 3-kinase/Akt pathway in thyroid cancer. Clinical Cancer Research 13 1161-1170.
18. Ito E, Iwahashi Y, Yanagisawa Y, Suzuki Y, Sugano S, Yuasa Y & Maruyama K 1999 Two short sequences have positive effects on the human p27Kip1 gene transcription. Gene 228 93-100.
19. Kawamata N, Morosetti R, Miller CW, Park D, Spirin KS, Nakamaki T, Takeuchi S, Hatta Y, Simpson J, Wilcyznski S et al. 1995 Molecular analysis of the cyclin-dependent kinase inhibitor gene p27/Kip1 in human malignancies. Cancer Research 55 2266-2269.
20. Khoo ML, Beasley NJ, Ezzat S, Freeman JL & Asa SL 2002 Overexpression of cyclin D1 and underexpression of p27 predict lymph node metastases in papillary thyroid carcinoma. Journal of Clinical Endocrinology and Metabolism 87 1814-1818.
21. Kibel AS, Suarez BK, Belani J, Oh J, Webster R, Brophy-Ebbers M, Guo C, Catalona WJ, Picus J & Goodfellow PJ 2003 CDKN1A and CDKN1B polymorphisms and risk of advanced prostate carcinoma. Cancer Research 63 2033-2036.
22. Kondo T, Ezzat S & Asa SL 2006 Pathogenetic mechanisms in thyroid follicular-cell neoplasia. Nature Reviews. Cancer 6 292-306.
23. Kossatz U & Malek NP 2007 p27: tumor suppressor and oncogene...? Cell Research 17 832-833.
24. Lee PH & Shatkay H 2008 F-SNP: computationally predicted functional SNPs for disease association studies. Nucleic Acids Research 36 D820-D824.
25. Li G, Sturgis EM, Wang LE, Chamberlain RM, Spitz MR, El-Naggar AK, Hong WK & Wei Q 2004 Association between the V109G polymorphism of the p27 gene and the risk and progression of oral squamous cell carcinoma. Clinical Cancer Research 10 3996-4002. (Pubitemid 38812473)
26. Lindberg D, Akerstrom G & Westin G 2007 Mutational analysis of p27 (CDKN1B) and p18 (CDKN2C) in sporadic pancreatic endocrine tumors argues against tumor-suppressor function. Neoplasia 9 533-535.
27. Liu Z, Dong Z, Han B, Yang Y, Liu Y & Zhang JT 2005 Regulation of expression by promoters versus internal ribosome entry site in the 50′-untranslated sequence of the human cyclin-dependent kinase inhibitor p27kip1. Nucleic Acids Research 33 3763-3771.
28. Liu Z, Hou P, Ji M, Guan H, Studeman K, Jensen K, Vasko V, El-Naggar AK & Xing M 2008 Highly prevalent genetic alterations in receptor tyrosine kinases and phosphatidylinositol 3-kinase/akt and mitogen-activated protein kinase pathways in anaplastic and follicular thyroid cancers. Journal of Clinical Endocrinology and Metabolism 93 3106-3116.
29. Livak KJ & Schmittgen TD 2001 Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods 25 402-408.
30. Millard SS, Vidal A, Markus M & Koff A 2000 A U-rich element in the 50′ untranslated region is necessary for the translation of p27 mRNA. Molecular and Cellular Biology 20 5947-5959.
31. Min YH, Cheong JW, Kim JY, Eom JI, Lee ST, Hahn JS, Ko YW & Lee MH 2004 Cytoplasmic mislocalization of p27Kip1 protein is associated with constitutive phosphorylation of Akt or protein kinase B and poor prognosis in acute myelogenous leukemia. Cancer Research 64 5225-5231.
32. Minami S, Ohtani-Fujita N, Igata E, Tamaki T & Sakai T 1997 Molecular cloning and characterization of the human p27Kip1 gene promoter. FEBS Letters 411 1-6.
33. Motti ML, Califano D, Troncone G, De Marco C, Migliaccio I, Palmieri E, Pezzullo L, Palombini L, Fusco A & Viglietto G 2005 Complex regulation of the cyclin-dependent kinase inhibitor p27kip1 in thyroid cancer cells by the PI3K/AKT pathway: regulation of p27kip1 expression and localization. American Journal of Pathology 166 737-749.
34. Mulligan LM, Kwok JB, Healey CS, Elsdon MJ, Eng C, Gardner E, Love DR, Mole SE, Moore JK, Papi L et al. 1993 Germ-line mutations of the RET proto-oncogene in multiple endocrine neoplasia type 2A. Nature 363 458-460. (Pubitemid 23179393)
35. Naidu R, Har YC & Taib NA 2007 P27 V109G polymorphism is associated with lymph node metastases but not with increased risk of breast cancer. Journal of Experimental & Clinical Cancer Research 26 133-140. (Pubitemid 46650054)
36. Nikiforov YE 2002 RET/PTC rearrangement in thyroid tumors. Endocrine Pathology 13 3-16.
37. Pagano M, Tam SW, Theodoras AM, Beer-Romero P, Del Sal G, Chau V, Yew PR, Draetta GF & Rolfe M 1995 Role of the ubiquitin-proteasome pathway in regulating abundance of the cyclin-dependent kinase inhibitor p27. Science 269 682-685.
38. Randolph GW & Maniar D 2000 Medullary carcinoma of the thyroid. Cancer Control 7 253-261.
39. Riesco-Eizaguirre G & Santisteban P 2007 Molecular biology of thyroid cancer initiation. Clinical and Translational Oncology 9 686-693.
40. Ruiz-Llorente S, Montero-Conde C, Milne RL, Moya CM, Cebrian A, Leton R, Cascon A, Mercadillo F, Landa I, Borrego S et al. 2007 Association study of 69 genes in the ret pathway identifies low-penetrance loci in sporadic medullary thyroid carcinoma. Cancer Research 67 9561-9567.
41. Sa G, Guo Y & Stacey DW 2005 The regulation of S phase initiation by p27Kip1 in NIH3T3 cells. Cell Cycle 4 618-627.
42. Sambrook J, Fritsch EF, Maniatis T, Irwin N & Maniatis T 1989 Molecular Cloning: A Laboratory Manual. Cold Spring Harbor, NY: Cold Spring Harbor Laboratory Press.
43. Santoro M, Rosati R, Grieco M, Berlingieri MT, D'Amato GL, de Franciscis V & Fusco A 1990 The ret proto-oncogene is consistently expressed in human pheochromocytomas and thyroid medullary carcinomas. Oncogene 5 1595-1598.
44. Slingerland J & Pagano M 2000 Regulation of the cdk inhibitor p27 and its deregulation in cancer. Journal of Cellular Physiology 183 10-17.
45. Spurdle AB, Deans AJ, Duffy D, Goldgar DE, Chen X, Beesley J, Easton DF, Antoniou AC, Peock S, Cook M et al. 2009 No evidence that CDKN1B (p27) polymorphisms modify breast cancer risk in BRCA1 and BRCA2 mutation carriers. Breast Cancer Research and Treatment 115 307-313.
46. Tallini G, Garcia-Rostan G, Herrero A, Zelterman D, Viale G, Bosari S & Carcangiu ML 1999 Downregulation of p27KIP1 and Ki67/Mib1 labeling index support the classification of thyroid carcinoma into prognostically relevant categories. American Journal of Surgical Pathology 23 678-685.
47. Tigli H, Buyru N & Dalay N 2005 Molecular analysis of the p27/kip1 gene in breast cancer. Molecular Diagnosis 9 17-21.
48. Viglietto G, Motti ML & Fusco A 2002 Understanding p27(kip1) deregulation in cancer: down-regulation or mislocalization. Cell Cycle 1 394-400.
49. Vitagliano D, Carlomagno F, Motti ML, Viglietto G, Nikiforov YE, Nikiforova MN, Hershman JM, Ryan AJ, Fusco A, Melillo RM et al. 2004 Regulation of p27Kip1 protein levels contributes to mitogenic effects of the RET/PTC kinase in thyroid carcinoma cells. Cancer Research 64 3823-3829.
50. Wang W, Spitz MR, Yang H, Lu C, Stewart DJ & Wu X 2007a Genetic variants in cell cycle control pathway confer susceptibility to lung cancer. Clinical Cancer Research 13 5974-5981.
51. Wang Y, Hou P, Yu H, Wang W, Ji M, Zhao S, Yan S, Sun X, Liu D, Shi B et al. 2007b High prevalence and mutual exclusivity of genetic alterations in the phosphatidylinositol- 3-kinase/akt pathway in thyroid tumors. Journal of Clinical Endocrinology and Metabolism 92 2387-2390. (Pubitemid 46997152)
52. Zeng YX, Somasundaram K & el-Deiry WS 1997 AP2 inhibits cancer cell growth and activates p21WAF1/CIP1 expression. Nature Genetics 15 78-82.